LOTEMAX
LOE Approachingloteprednol etabonate
NDAOPHTHALMICSUSPENSION/DROPS
Approved
Mar 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
16
Clinical Trials (5)
Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery
Started Apr 2018
381 enrolled
Inflammation Following Ocular Surgery
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Started Sep 2014
326 enrolled
InflammationPainCataract
Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
Started Apr 2014
10 enrolled
Sjogren's Disease
Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Started May 2013
102 enrolled
Keratoconjunctivitis Sicca
Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation
Started Jan 2013
12 enrolled
Pharmacokinetics